title: [Invasive mould disease in haematological patients].
abstract: Invasive mould infections (IMI) are a persistent problem with high morbidity and mortality rates among patients receiving chemotherapy for hematological malignancies and hematopoietic stem cell transplant recipients. Management of IMI in this setting has become increasingly complex with the advent of new antifungal agents and diagnostic tests, which have resulted in different therapeutic strategies (prophylactic, empirical, pre-emptive, and directed). A proper assessment of the individual risk for IMI appears to be critical in order to use the best prophylactic and therapeutic approach and increase the survival rates. Among the available antifungal drugs, the most frequently used in the hematologic patient are fluconazole, mould-active azoles (itraconazole, posaconazole and voriconazole), candins (anidulafungin, caspofungin and micafungin), and lipid formulations of amphotericin B. Specific recommendations for their use, and criteria for selecting the antifungal agents are discussed in this paper.
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic address: isabelruizcamps@gmail.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Ruiz-Camps
authors.affiliation: Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, España.
authors.forename: Isidro
authors.initials: I
authors.lastname: Jarque
mesh_terms: D000935:Antifungal Agents / Q000145:classification / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D021821:Communicable Diseases, Emerging / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology / Q000517:prevention & control; D006402:Hematologic Diseases / Q000150:complications* / Q000276:immunology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D009091:Mucormycosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D012307:Risk Factors; D021681:Scedosporium / Q000302:isolation & purification
chemical_list: D000935:Antifungal Agents
keywords: Enfermedad fúngica invasora; Filamentous fungi; Hematological malignancies; Hematopoietic stem cell transplant; Hongos filamentosos; Invasive fungal disease; Neoplasias hematológicas; Trasplante de progenitores hematopoyéticos